Hengrui is proud!

Recently, Hengrui Pharmaceuticals has good news successively: it has been listed on the top 50 global pharmaceutical companies in 2021 and its ranking has risen, PD-1 won the sixth indication, and Azilsartan tablets won the first imitation
.

The adjustment of the 2021 medical insurance catalogue has been started, and 4 new domestic PD-1 indications will prepare for medical insurance negotiations

Hengrui PD-1 won the sixth indication, 4 major PD-1 medical insurance highlights

On June 10, the NMPA official website showed that Hengrui Medicine's carrelizumab for injection was approved for new indications: combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal cancer, becoming a global The first PD-1 inhibitor approved for the first-line nasopharyngeal carcinoma indication
.

This is the sixth indication that Carrelizumab has won after Hodgkin's lymphoma, liver cancer, lung cancer, esophageal squamous cell carcinoma, second-line and above nasopharyngeal carcinoma

Comparing the other three domestic PD-1 inhibitors, terelimumab, sintilizumab and tislelizumab, carrelizumab not only has the most approved indications, but also leads in sales
.

In 2020, the sales revenue of treplizumab will be 1.

The adjustment of the 2021 medical insurance catalogue has been started and can be included in the review scope including: from January 1, 2016 to June 30, 2021, approved by the national drug regulatory authority, the indications or functions and indications of the drugs have undergone major changes
.

This means that the third-line nasopharyngeal carcinoma and first-line nasopharyngeal carcinoma indications approved by carrelizumab this year are expected to enter medical insurance

It is worth noting that Sindilimab’s Sintilimab is the first PD-1 inhibitor to enter the medical insurance catalog.
The validity of the agreement will expire this year, and the classic Hodgkin’s lymphoma indication will be newly approved.
The first-line non-squamous non-small cell lung cancer and first-line squamous non-small cell lung cancer indications participated in the medical insurance negotiations
.

Tilelizumab first-line squamous non-small cell, teriprizumab third-line nasopharyngeal carcinoma and urothelial carcinoma and other newly approved indications this year will also participate in medical insurance negotiations

Progress of 4 domestic PD-1 indications

8 centralized harvest varieties are ready to go against Qilu, Yangtze River and Zhengda Tianqing

The competitive landscape of Hengrui Medicine's fifth batch of centralized procurement varieties

Note: If the sales are less than 30 million yuan, use * to represent

The fifth batch of centralized procurement will be opened in Shanghai on June 23.

Hengrui Medicine has 8 over-evaluated products involved, including oxaliplatin injection, cisatracurium benzenesulfonate injection, and iodixanol injection , Dutasteride soft capsule, docetaxel injection, glycopyrrolate injection, ropivacaine hydrochloride injection and palonosetron hydrochloride injection

Among the 8 varieties, 5 corresponding generic drugs will have a terminal sales of more than 1 billion yuan in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020, respectively.

Oxaliplatin, cisatracurium benzenesulfonate, iodixanol, docetaxel and palonosetron

In addition, Hengrui Medicine's dutasteride soft capsules and glycopyrrolate injection were approved for marketing in 2021 and 2020, respectively, and the market is almost blank.

Ropivacaine hydrochloride injection and palonosetron hydrochloride injection The two varieties also have a low market share

In terms of competition, only two companies have reviewed dutasteride soft capsules, and 3 companies have reviewed oxaliplatin injection and glycopyrrolate injection.
The competition pattern is relatively good
.
Docetaxel injections, ropivacaine injections, palonosetron injections, iodixanol injections and other varieties have not only a large market, but also fierce competition
.
We will wait and see how Hengrui Medicine will act
.

R&D investment in the first quarter soared by 62.
26%! 3 new class 1 drugs can be expected

Hengrui Medicine Pending Approval of Class 1 New Drugs

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

In recent years, Hengrui Pharmaceuticals has continued to increase R&D investment.
In 2020, it has invested a total of 4.
989 billion yuan in R&D, an increase of 28.
04% year-on-year, and R&D investment accounted for 17.
99% of sales revenue
.
In the first quarter of 2021, the company invested 1.
316 billion yuan in research and development, a year-on-year increase of 62.
26%
.

At present, Hengrui Medicine has 7 innovative drugs, including Irecoxib, apatinib, thiopefigrastim, pirotinib, carrelizumab, remazolam and fluzoparib
.
Among them, carrelizumab and fluzoparib have multiple indications under development
.

For Hengrui Pharmaceuticals in 2021, in addition to PD-1 indications expansion, medical insurance negotiations, and centralized procurement of key varieties, the approval of new products is also crucial
.
According to data from Minai.
com, Hengrui Medicine has 3 new category 1 drugs whose marketing applications are under review and approval, including Hytrapopaparolamine Tablets, Retagliptin Phosphate Tablets, and Henggligliflozin Proline Tablets.
Approved for listing this year
.